# Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU in Healthy Subjects

> **NCT02183103** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** meloxicam rapid release tablet, 12mg, UH AC62MU

## Key facts

- **NCT ID:** NCT02183103
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 1999-05
- **Final completion:** —
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183103, "Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*